Should I buy GE HealthCare stock in 2025? Comprehensive UAE Guide

What is GE HealthCare?

¹Based on a 16.3% adjusted EBIT margin as reported for FY 2024.

How much is the GE HealthCare stock?

The price of GE HealthCare stock is rising this week. Currently, GEHC is trading at $71.53, up $0.38 (+0.53%) in the past 24 hours and showing a strong 2.80% increase over the last week.

Investors in the UAE should be aware that recent momentum and moderate volatility can create both risks and attractive opportunities in this sector.

Our complete analysis of the GE HealthCare stock

Having thoroughly reviewed GE HealthCare Technologies Inc.'s most recent financial disclosures alongside its three-year stock trajectory, our proprietary multi-factor analysis—melding financial benchmarks, technical signals, sector data, and peer comparisons—offers a compelling view. This integrated approach, which synthesizes both momentum and fundamentals within the global healthcare technology landscape, is designed to unlock robust insight for diversified investors. So, why might GE HealthCare stock once again become a strategic entry point into the healthtech sector in 2025?

Recent Performance and Market Context

Over the past year, GE HealthCare (NASDAQ: GEHC) has delivered a dynamic stock performance, punctuated by marked resilience and adaptability within the health technology sector. As of May 30, 2025, GEHC trades at $71.53, having recently bounced by +2.80% over one week and +5.05% over one month. Although the past six months saw a -14.05% retracement amid sector-wide volatility, the one-year change stands at a manageable -8.82%, a testament to the company’s defensive DNA despite macro headwinds.

Notably, GE HealthCare’s Q1 2025 results exceeded expectations, with organic revenue growth of 3%, adjusted EBIT margin expanding to 15% (versus 14.7% last year), and diluted EPS surging 51.9% YoY. The company’s robust order book (+10% YoY growth in orders) spots a favorable demand trend, while major events—a completed acquisition of Nihon Medi-Physics, the US launch of the Flyrcado™ imaging agent, and $1 billion in authorized share buybacks—reinforce the bullish case.

The current macroeconomic landscape enhances this context: healthcare spending remains on a secular growth trajectory, with technology-driven precision medicine, AI-powered diagnostics, and global public health investment supporting fundamental demand. In GCC markets and especially the UAE, there is surging appetite for exposure to advanced healthcare technology, underpinned by ambitious local healthcare infrastructure projects and strong institutional partnerships with Western innovators.

Technical Analysis

On the technical front, GEHC’s charts suggest a positive inflection point may be near. The 14-day RSI reads 52.70—firmly neutral and far from overbought levels—hinting at balanced buyer-seller dynamics and the potential for upward pivot. The MACD stands at 0.25, presently offering a slight sell signal, but this comes after recent upward moves and appears more corrective than structural.

Crucially, the stock is now trading above its 20-day ($70.87) and 50-day ($70.63) moving averages—both newly re-crossed bullish thresholds—while still below the 100-day ($78.74) and 200-day ($82.11) moving averages, which serve as longer-term resistance targets. The strong technical support zone at $70.22 appears to be firmly defended, having held across multiple tests, while the immediate resistance sits proximate at $72.66—a level a decisive break above could signal renewed medium-term momentum. Looking further out, the 52-week high ($94.80) represents a formidable aspirational target, with support at $57.65 providing a substantial technical floor.

Short- and medium-term price structures indicate a constructive setup for investors seeking a catalyst-driven rebound, with the potential for a bullish trend resumption as technical posture strengthens.

Fundamental Analysis

GE HealthCare’s fundamentals are a solid foundation for long-term value creation. For the trailing twelve months (TTM, as of May 2025):

• Revenue: $19.7 billion (+1% YoY, organic growth)
• Adjusted EBIT margin: 16.3% (vs. 15.1% prior year; Q1 2025 at 15.0%)
• TTM EPS: $4.76
• TTM P/E: 15.03, impressively attractive relative to historical and peer multiples.
• Projected 2025 EPS: $3.90–$4.10

Despite modest short-term headwinds from tariffs and a softer Chinese market, GEHC’s core business remains highly cash-generative, with free cash flow at $1.6 billion annually (and at least $1.2 billion expected in 2025). The balance sheet is robust, supporting continued investment and shareholder returns.

A 0.20% dividend yield, while modest, signals ongoing commitment to shareholder value, complemented by large-scale stock buybacks. With over 125 years of healthcare innovation and a portfolio spanning imaging, patient care solutions, diagnostics, and advanced visualization, the company’s market leadership is widely recognized. This is evidenced by frequent inclusion in the Fortune World’s Most Admired Companies list, further solidifying its premium brand status.

Valuation metrics, including a P/E of 15 and consensus analyst target price of $88.27 (+23.4% upside from current levels, with a range of $74–$115), reinforce that the stock remains attractively priced for renewed accumulation.

Volume and Liquidity

GE HealthCare benefits from strong institutional sponsorship, with a public float of approximately 456 million shares and an average daily volume of 4.99 million shares. This high liquidity underpins investor confidence and makes the stock a practical candidate for both active and longer-term market participants.

The broad and stable base of institutional holders, alongside ready liquidity, ensures the company is well placed for dynamic valuation moves should catalysts materialize. This is especially relevant for investors in the UAE and wider GCC, where capital mobility and access to global equities are at unprecedented highs.

Catalysts and Positive Outlook

A series of tangible and forward-looking growth catalysts set GE HealthCare apart in the current landscape:

• AI-Driven Innovation: Continued development of artificial intelligence-powered imaging and diagnostics, positioning the company to capture the next wave of healthcare digitalization.
• Radiopharmaceutical Expansion: The recent acquisition of Nihon Medi-Physics propels GEHC into the rapidly growing radiopharmaceutical space, especially in the Asia-Pacific region.
• Product Pipeline: Launch of Flyrcado™ in the US opens a significant new addressable market in cardiology imaging.
• Strategic Partnerships: Deepening commercial partnerships with renowned healthcare providers in the US (Sutter Health) and UK (Nuffield Health) lay groundwork for global expansion.
• Precision Care Strategy: A strong focus on precision medicine aligns with both regulatory tailwinds and shifting payer dynamics, potentially accelerating adoption.
• ESG Commitment: Well-articulated environmental and social strategies strengthen its appeal to global capital pools, particularly from ESG-conscious investors in emerging market hubs.

Importantly, the company is proactively mitigating the impact of tariff regimes and supply chain disruptions, with 2025 guidance for organic revenue growth of 2–3%, EBIT margins of 14.2–14.4%, and robust free cash flow. The authorized $1 billion share repurchase program adds further upside as buybacks support both the share price and EPS.

Investment Strategies

Given the current setup, several arguments favor a range of entry points for different investor profiles:

• Short-term position:
• The share price is consolidating above strong support with positive momentum signals (e.g., recapture of key moving averages).
• Upcoming technical breaks (above $72.66) may trigger momentum buying.
• Medium-term horizon:
• The next quarters are likely to be marked by key product launches, integration of the NMP acquisition, and ongoing buyback activity.
• Analyst upgrades, earnings releases, or positive macro developments could serve as catalysts for re-rating toward consensus targets.
• Long-term accumulation:
• GE HealthCare sits at the crossroads of defensiveness and high innovation—an ideal complement to portfolios seeking resilient, growth-oriented exposure.
• The compelling P/E, strong cash flows, market leadership, and deep commitment to R&D make it a structural play on global healthcare transformation.

From a tactical standpoint, the current level near $71.53 is just above fundamental and technical support zones, suggesting limited downside risk while positioning investors ahead of possible upside triggers.

Is it the Right Time to Buy GE HealthCare?

In sum, GE HealthCare combines resilient financial fundamentals, strong technical underpinnings, and a plethora of catalysts that justify renewed attention from sophisticated investors. With robust order flows, innovation momentum, strategic acquisitions, and compelling valuation, the stock seems to represent an excellent opportunity at current levels—particularly as it hovers near support and just below its intrinsic consensus value.

The favorable macro environment for healthtech, especially in rapidly evolving markets like the UAE, further bolsters the buy-side narrative—offering exposure to global trends while riding the next wave of sector innovation.

For investors seeking a high-quality health technology leader capable of delivering both resilience and upside in an uncertain world, the case for considering GE HealthCare as a strategic addition to the portfolio appears increasingly strong.

Seizing this moment to closely evaluate GE HealthCare may prove rewarding as the company enters a new phase of technical and fundamental momentum, positioning itself at the forefront of healthcare’s digital transformation.

How to buy GE HealthCare stock in the UAE?

Buying shares of GE HealthCare Technologies Inc. (GEHC) online is simple and secure for investors in the United Arab Emirates, thanks to modern, regulated brokers. You can access global markets from your computer or phone, benefit from robust investor protections, and choose the method best suited to your goals: either buying shares outright (spot buying) or trading using Contracts for Difference (CFDs). Each approach has its own features, which we explain below—along with a broker comparison available further down the page to help you choose.

Spot Buying

Spot buying refers to purchasing GE HealthCare shares directly via a brokerage platform. As their legal owner, you benefit from all dividends and potential capital gains, and your investment is tied to the actual share price. For UAE investors, most top brokers charge a fixed commission per transaction, often around $5–$10 (about AED 18–37) per order.

Example

If GE HealthCare is trading at $71.53 per share, a $1,000 investment—after a typical $5 fee—lets you buy approximately 13 shares ([$1,000 – $5] ÷ $71.53 ≈ 13.9 shares, rounded down to 13).

✔️ Gain scenario: If the share price rises by 10%, your shares are now worth about $1,100 in total.

Result: +$100 gross gain, or +10% on your investment.

Trading via CFD

CFDs (Contracts for Difference) allow you to speculate on GE HealthCare’s share price without owning the shares. Instead, you enter into a contract with your broker to exchange the price difference from your position’s opening to closing. CFDs offer leverage (borrowed funds), which can multiply gains and losses. Key fees include the “spread” (difference between buy and sell prices) and daily overnight financing if you hold positions beyond the trading day.

Example

You decide to trade GE HealthCare CFDs with a $1,000 deposit and 5x leverage, giving you $5,000 in market exposure.

✔️ Gain scenario: If GE HealthCare’s price rises by 8%, your CFD position would earn 8% × 5 = 40%.

Result: That’s a $400 gain on your $1,000 stake (excluding fees).

Final Advice

Before investing, it’s wise to compare brokers’ fees, features, and support for UAE-based clients—look out for differences in commissions, spreads, and available tools. Your choice depends on your investing style: direct share ownership suits longer-term investors, while CFDs offer flexibility and leverage for active traders—see our full broker comparison further down the page for guidance. Always invest within your means, and review all conditions carefully to make an informed decision.

Our 7 tips for buying GE HealthCare stock

The latest news about GE HealthCare

GE HealthCare stock advanced 2.8% over the past week, outperforming the broader market on renewed buying interest. The share price closed at $71.53, with recent trading benefiting from both technical momentum and positive investor sentiment following the company’s quarterly results and strategic announcements. Notably, the stock remains above its key 20 and 50-day moving averages, both flashing buy signals, while also consolidating above an important support level at $70.22, indicating underlying demand.

GE HealthCare reported a robust Q1 2025, exceeding expectations with strong organic growth and surging earnings. Revenue reached $4.8 billion with 3% organic growth, and diluted EPS soared by 51.9% year-on-year to $1.23. Commanding particular note was the 10% jump in order growth, signifying resilient demand in core markets. The company’s margins also improved versus the previous year, reflecting solid operational execution despite a lower free cash flow compared to Q1 2024. This financial momentum supports confidence in GE HealthCare’s global business prospects and is consistent with the recent analyst consensus, which maintains a bullish outlook and a target price representing more than 23% upside.

The completion of the Nihon Medi-Physics acquisition and new product launches highlight GE HealthCare’s commitment to innovation and international expansion. In recent days, the company finalized the acquisition of leading Japanese radiopharmaceutical firm Nihon Medi-Physics, strengthening its diagnostics portfolio and foothold in Asia. Simultaneously, GE HealthCare commenced the US rollout of Flyrcado™ (flurpiridaz F 18) for cardiac imaging—an innovation likely to enrich its offering to hospitals, including those in the Middle East that prioritize advanced diagnostic solutions and value partnerships with global leaders.

Strategic share buyback and continued focus on AI-driven imaging position GE HealthCare for investor value creation and leadership in precision care. The board’s recent authorization of a $1 billion share repurchase program signals confidence in the company’s intrinsic value and future cash flows. Alongside this, GE HealthCare is sustaining its investment in AI-powered medical imaging, a sector of acute interest in the UAE and GCC given national healthcare digitalization agendas, and where GE HealthCare already supplies advanced imaging equipment to public and private sector providers.

Market analysts reaffirmed a ‘Strong Buy’ consensus, citing resilient fundamentals and relevance to the UAE’s evolving healthcare sector. Ten analysts now rate GE HealthCare as a buy, with a consensus price target of $88.27. The company’s well-diversified product range, established partnerships, S&P 500 and NASDAQ 100 inclusion, and global expansion through innovation and acquisitions are recognized as catalysts, especially as regional institutions in the UAE look to upgrade and localize their advanced diagnostics capabilities with GE HealthCare solutions.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.